Literature DB >> 19562241

Alendronate-related femoral diaphysis fracture--what should be done to predict and prevent subsequent fracture of the contralateral side?

M H Edwards1, F C McCrae, S A Young-Min.   

Abstract

INTRODUCTION: Atypical fractures of the femoral diaphysis have recently been associated with alendronate therapy (Neviaser et al. J Orthop Trauma 22(5):346-350, 2008; Kwek et al. Injury 39:224-231, 2008; Lenart et al. N Engl J Med 358:1304-1306, 2008).
METHODS: In many cases, fractures have occurred bilaterally prompting debate regarding appropriate screening of the unaffected side (Kwek et al. N Engl J Med 359(3):316-317, 2008). CASE REPORT: We report a case of sequential, bilateral, femoral diaphysis fractures associated with prolonged alendronate therapy and the failure to predict the subsequent fracture of the contralateral side despite radiological imaging. DISCUSSION: We review the current literature and discuss potential management strategies.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19562241     DOI: 10.1007/s00198-009-0986-y

Source DB:  PubMed          Journal:  Osteoporos Int        ISSN: 0937-941X            Impact factor:   4.507


  11 in total

1.  Imaging bone microdamage in vivo with positron emission tomography.

Authors:  Jiliang Li; Michael A Miller; Gary D Hutchins; David B Burr
Journal:  Bone       Date:  2005-10-19       Impact factor: 4.398

2.  Detection of trabecular bone microdamage by micro-computed tomography.

Authors:  Xiang Wang; Daniel B Masse; Huijie Leng; Kevin P Hess; Ryan D Ross; Ryan K Roeder; Glen L Niebur
Journal:  J Biomech       Date:  2007-06-22       Impact factor: 2.712

3.  Atypical fractures of the femoral diaphysis in postmenopausal women taking alendronate.

Authors:  Brett A Lenart; Dean G Lorich; Joseph M Lane
Journal:  N Engl J Med       Date:  2008-03-20       Impact factor: 91.245

4.  More on atypical fractures of the femoral diaphysis.

Authors:  Ernest B K Kwek; Joyce S B Koh; Tet Sen Howe
Journal:  N Engl J Med       Date:  2008-07-17       Impact factor: 91.245

5.  Severely suppressed bone turnover: a potential complication of alendronate therapy.

Authors:  Clarita V Odvina; Joseph E Zerwekh; D Sudhaker Rao; Naim Maalouf; Frank A Gottschalk; Charles Y C Pak
Journal:  J Clin Endocrinol Metab       Date:  2004-12-14       Impact factor: 5.958

6.  A non-invasive in vitro technique for the three-dimensional quantification of microdamage in trabecular bone.

Authors:  S Y Tang; D Vashishth
Journal:  Bone       Date:  2007-02-27       Impact factor: 4.398

7.  Low bone mineral density is associated with bone microdamage accumulation in postmenopausal women with osteoporosis.

Authors:  Jan J Stepan; David B Burr; Imre Pavo; Adrien Sipos; Dana Michalska; Jiliang Li; Astrid Fahrleitner-Pammer; Helmut Petto; Michael Westmore; David Michalsky; Masahiko Sato; Harald Dobnig
Journal:  Bone       Date:  2007-05-18       Impact factor: 4.398

8.  Low-energy femoral shaft fractures associated with alendronate use.

Authors:  Andrew S Neviaser; Joseph M Lane; Brett A Lenart; Folorunsho Edobor-Osula; Dean G Lorich
Journal:  J Orthop Trauma       Date:  2008 May-Jun       Impact factor: 2.512

9.  An emerging pattern of subtrochanteric stress fractures: a long-term complication of alendronate therapy?

Authors:  Ernest Beng Kee Kwek; Seo Kiat Goh; Joyce Suang Bee Koh; Meng Ai Png; Tet Sen Howe
Journal:  Injury       Date:  2008-01-28       Impact factor: 2.586

10.  Subtrochanteric and diaphyseal femur fractures in patients treated with alendronate: a register-based national cohort study.

Authors:  Bo Abrahamsen; Pia Eiken; Richard Eastell
Journal:  J Bone Miner Res       Date:  2009-06       Impact factor: 6.741

View more
  14 in total

1.  Paget's Disease of Bone: A Review of Epidemiology, Pathophysiology and Management.

Authors:  Joseph L Shaker
Journal:  Ther Adv Musculoskelet Dis       Date:  2009-04       Impact factor: 5.346

Review 2.  A framework for the development of guidelines for the management of glucocorticoid-induced osteoporosis.

Authors:  S Lekamwasam; J D Adachi; D Agnusdei; J Bilezikian; S Boonen; F Borgström; C Cooper; A Diez Perez; R Eastell; L C Hofbauer; J A Kanis; B L Langdahl; O Lesnyak; R Lorenc; E McCloskey; O D Messina; N Napoli; B Obermayer-Pietsch; S H Ralston; P N Sambrook; S Silverman; M Sosa; J Stepan; G Suppan; D A Wahl; J E Compston
Journal:  Osteoporos Int       Date:  2012-03-21       Impact factor: 4.507

Review 3.  Interventions to prevent and treat corticosteroid-induced osteoporosis and prevent osteoporotic fractures in Duchenne muscular dystrophy.

Authors:  Jennifer M Bell; Michael D Shields; Janet Watters; Alistair Hamilton; Timothy Beringer; Mark Elliott; Rosaline Quinlivan; Sandya Tirupathi; Bronagh Blackwood
Journal:  Cochrane Database Syst Rev       Date:  2017-01-24

4.  Femoral insufficiency fractures associated with prolonged bisphosphonate therapy.

Authors:  Joseph D Isaacs; Louis Shidiak; Ian A Harris; Zoltan L Szomor
Journal:  Clin Orthop Relat Res       Date:  2010-08-31       Impact factor: 4.176

5.  Changing pattern of femoral fractures in osteogenesis imperfecta with prolonged use of bisphosphonates.

Authors:  N Nicolaou; Y Agrawal; M Padman; J A Fernandes; M J Bell
Journal:  J Child Orthop       Date:  2012-01-17       Impact factor: 1.548

Review 6.  Bisphosphonates for treatment of osteoporosis: expected benefits, potential harms, and drug holidays.

Authors:  Jacques P Brown; Suzanne Morin; William Leslie; Alexandra Papaioannou; Angela M Cheung; Kenneth S Davison; David Goltzman; David Arthur Hanley; Anthony Hodsman; Robert Josse; Algis Jovaisas; Angela Juby; Stephanie Kaiser; Andrew Karaplis; David Kendler; Aliya Khan; Daniel Ngui; Wojciech Olszynski; Louis-Georges Ste-Marie; Jonathan Adachi
Journal:  Can Fam Physician       Date:  2014-04       Impact factor: 3.275

Review 7.  Subtrochanteric fractures after long-term treatment with bisphosphonates: a European Society on Clinical and Economic Aspects of Osteoporosis and Osteoarthritis, and International Osteoporosis Foundation Working Group Report.

Authors:  R Rizzoli; K Akesson; M Bouxsein; J A Kanis; N Napoli; S Papapoulos; J-Y Reginster; C Cooper
Journal:  Osteoporos Int       Date:  2010-11-18       Impact factor: 4.507

8.  Safety and tolerability of zoledronic acid and other bisphosphonates in osteoporosis management.

Authors:  Luca Dalle Carbonare; Mirko Zanatta; Adriano Gasparetto; Maria Teresa Valenti
Journal:  Drug Healthc Patient Saf       Date:  2010-08-19

9.  Prevalence and Risk Factors of Atypical Femoral Fracture Bone Scintigraphic Feature in Patients Experiencing Bisphosphonate-Related Osteonecrosis of the Jaw.

Authors:  Chang-Hee Lee; Seung Hyun Son; Chae Moon Hong; Ju Hye Jeong; Shin Young Jeong; Sang-Woo Lee; Jaetae Lee; Tae-Geon Kwon; Byeong-Cheol Ahn
Journal:  Nucl Med Mol Imaging       Date:  2018-07-16

Review 10.  Do bisphosphonates cause femoral insufficiency fractures?

Authors:  Andreas Seraphim; Nawfal Al-Hadithy; Simon C Mordecai; Shafic Al-Nammari
Journal:  J Orthop Traumatol       Date:  2012-08-01
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.